利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.085 秒)

    Sirtuin modulating compounds
    2.
    发明授权
    Sirtuin modulating compounds 有权
    沉默调节蛋白调节化合物

    公开(公告)号：US08044198B2

    公开(公告)日：2011-10-25

    申请号：US12070350

    申请日：2008-02-15

    申请人： Joseph J. Nunes ,  Jill Milne ,  Jean Bemis ,  Roger Xie ,  Chi B. Vu ,  Pui Yee Ng ,  Jeremy S. Disch

    发明人： Joseph J. Nunes ,  Jill Milne ,  Jean Bemis ,  Roger Xie ,  Chi B. Vu ,  Pui Yee Ng ,  Jeremy S. Disch

    IPC分类号： C07D237/26 ,  A61K31/50

    CPC分类号： C07D235/18 ,  C07D401/12 ,  C07D403/12 ,  C07D513/04

    摘要： Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

    摘要翻译： 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命，以及治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 心血管疾病，血液凝固障碍，炎症，癌症和/或潮红以及将受益于增加的线粒体活性的疾病或病症。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

    SIRTUIN MODULATING COMPOUNDS
    4.
    发明申请
    SIRTUIN MODULATING COMPOUNDS 有权
    SIRTUIN调节化合物

    公开(公告)号：US20120022254A1

    公开(公告)日：2012-01-26

    申请号：US13249131

    申请日：2011-09-29

    申请人： Joseph J. Nunes ,  Jill Milne ,  Jean Bemis ,  Roger Xie ,  Chi B. Vu ,  Pui Yee Ng ,  Jeremy S. Disch

    发明人： Joseph J. Nunes ,  Jill Milne ,  Jean Bemis ,  Roger Xie ,  Chi B. Vu ,  Pui Yee Ng ,  Jeremy S. Disch

    IPC分类号： C07D513/04

    CPC分类号： C07D235/18 ,  C07D401/12 ,  C07D403/12 ,  C07D513/04

    摘要： Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

    摘要翻译： 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命，以及治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 心血管疾病，血液凝固障碍，炎症，癌症和/或潮红以及将受益于增加的线粒体活性的疾病或病症。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

    Sirtuin modulating compounds
    7.
    发明授权
    Sirtuin modulating compounds 有权
    沉默调节蛋白调节化合物

    公开(公告)号：US07345178B2

    公开(公告)日：2008-03-18

    申请号：US11499919

    申请日：2006-08-04

    申请人： Joseph J. Nunes ,  Jill Milne ,  Jean Bemis ,  Roger Xie ,  Chi B. Vu ,  Pui Yee Ng ,  Jeremy S. Disch

    发明人： Joseph J. Nunes ,  Jill Milne ,  Jean Bemis ,  Roger Xie ,  Chi B. Vu ,  Pui Yee Ng ,  Jeremy S. Disch

    IPC分类号： C07D513/00 ,  A01N43/78

    CPC分类号： C07D235/18 ,  C07D401/12 ,  C07D403/12 ,  C07D513/04

    摘要： Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

    摘要翻译： 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命，以及治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 心血管疾病，凝血障碍，炎症，癌症和/或潮红以及由线粒体活性增加所致的疾病或病症。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。